Kymera Therapeutics (NASDAQ: KYMR) reported a $132.0 million net loss for the third quarter ended September 30, 2026, compared with a $82.2 million loss a year earlier. The company recorded no collaboration revenue in the quarter and held $1.6 billion in cash, cash equivalents and investments.
Kymera also reported positive Phase 1 healthy-volunteer results for KT-579, its oral IRF5 degrader, and plans to begin the LUMORA Phase 1b lupus trial by early 2027.
- Third-quarter net loss per share was $1.32, basic and diluted, versus $0.94 a year earlier.
- Research and development expense was $128.5 million, up from $74.1 million in the prior-year quarter.
- The last patient completed the week 16 visit in the KT-621 BROADEN2 Phase 2b atopic dermatitis trial; topline data are planned by year-end 2026.
- KT-621 BREADTH Phase 2b asthma topline data are expected in late 2027.
- Kymera expects its cash balance to provide runway into 2029.
$KYMR Insider Trading Activity
$KYMR insiders have traded $KYMR stock on the open market 161 times in the past 6 months. Of those trades, 0 have been purchases and 161 have been sales.
Here’s a breakdown of recent trading of $KYMR stock by insiders over the last 6 months:
- BRUCE BOOTH has made 0 purchases and 123 sales selling 1,738,973 shares for an estimated $187,277,531.
- PARTNERS L P/IL BVF has made 0 purchases and 4 sales selling 1,630,658 shares for an estimated $173,665,077.
- NELLO MAINOLFI (Chief Executive Officer) has made 0 purchases and 12 sales selling 160,000 shares for an estimated $18,587,444.
- BRUCE N. JACOBS (Chief Financial Officer) has made 0 purchases and 8 sales selling 77,109 shares for an estimated $8,864,828.
- JEREMY G CHADWICK (Chief Operating Officer) has made 0 purchases and 7 sales selling 17,184 shares for an estimated $1,373,289.
- NOAH GOODMAN (Chief Business Officer) has made 0 purchases and 4 sales selling 10,889 shares for an estimated $1,204,828.
- BRIAN ADAMS (Chief Legal Officer) has made 0 purchases and 3 sales selling 6,371 shares for an estimated $744,297.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$KYMR Hedge Fund Activity
We have seen 145 institutional investors add shares of $KYMR stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 6,160,428 shares (+6361.9%) to their portfolio in Q2 2026, for an estimated $706,416,278
- ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC removed 1,730,467 shares (-37.8%) from their portfolio in Q2 2026, for an estimated $198,432,650
- BVF INC/IL removed 1,630,658 shares (-29.6%) from their portfolio in Q2 2026, for an estimated $186,987,552
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,052,133 shares (+17.4%) to their portfolio in Q2 2026, for an estimated $120,648,091
- NORGES BANK added 740,703 shares (+4477.4%) to their portfolio in Q2 2026, for an estimated $84,936,413
- FMR LLC added 649,306 shares (+5.5%) to their portfolio in Q2 2026, for an estimated $74,455,919
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 561,170 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $64,349,363
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
